Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.
In a statement Tuesday, T2 Biosystems TTOO announced that it has received 510(k) clearance from the FDA for its T2Biothreat panel. The panel is a direct-from-blood molecular diagnostic test that detects six biothreat pathogens, including the organisms that cause anthrax, plague and typhus.
With…
Read the full article here
